Intraocular Pressure
6
Pipeline Programs
4
Companies
5
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
U
ILEVROApproved
nepafenac
Unknown CompanyNonsteroidal Anti-inflammatory Drug [EPC]ophthalmic2012
U
NEVANACApproved
nepafenac
Unknown CompanyNonsteroidal Anti-inflammatory Drug [EPC]ophthalmic2005
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Bausch + LombNJ - Bridgewater
2 programs1
1
BOL-303259-XPhase 21 trial
Latanoprostene bunodPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
T-Therapeuticsnepafenac
Bausch + LombBOL-303259-X
Bausch + LombLatanoprostene bunod
AstellasMirabegron
New World Medicalab interno canaloplasty
Clinical Trials (5)
Total enrollment: 800 patients across 5 trials
Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes
Start: Dec 2012Est. completion: Apr 2013
Phase 4Completed
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
Start: Dec 2010Est. completion: Jun 2012413 patients
Phase 2Completed
Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
Start: Jul 2013Est. completion: Oct 201324 patients
Phase 1Completed
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
Start: Nov 2010Est. completion: Feb 2011321 patients
Phase 1Completed
A FIH Trial of the STREAMLINE™ SURGICAL SYSTEM
Start: Dec 2020Est. completion: Sep 202242 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space